BCTX News and Press, BriaCell Therapeutics Corp.

SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...

2024-05-28 08:48:33 ET Marpai ( MRAI ) -41% on notice of delisting or failure to satisfy a continued listing rule . OneMedNet ( ONMD ) -20% . Gold Royalty ( GROY ) -15% after agreeing to acquire a copper stream on the Vares silver project , oper...

2024-05-28 08:45:28 ET More on Briacell Therapeutics, BeiGene, etc. BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BriaCell falls on $5M stock offering BeiGene, AbbVie patent spat to get trial from USPTO appeals board Seeking Alpha’s Quant Rat...

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq...

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies 1,2,...

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...

2024-05-15 13:42:32 ET More on Briacell Therapeutics Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics Read the full article on Seeking Alpha ...

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...